摘要
The reaction of the reduced Schiff base HL（N-（4-hydroxybenzyl）-L-serine） with Zn（CH3COO）2·2H2O in aqueous solution afforded [Zn（L）2]·3H2O（I）. The complex has been characterized by elemental analysis, FT-IR, powder X-ray diffraction, electrospray ionization mass spectrometry and single-crystal X-ray diffraction. Complex I crystallizes in the orthorhombic system, space group P212121, with a=9.197（2）, b=10.445（2）, c=24.149（5） , V=2319.8（8） 3, Z=4, C（20）H（30）N2O11 Zn, Mr=539.83, Dc=1.546 g·cm3, μ=1.122 mm（-1）, F（000）=1128, GOOF=0.971, the final R=0.0206 and w R=0.0506 for 4346 observed reflections（I ＆gt; 2σ（I））. In complex I, each Zn（II） ion coordinates with three carboxyl oxygen atoms and two amine nitrogen atoms from three L-anions, forming a distorted five-coordinated trigonal bipyramidal geometry. Complex I exhibits a 1D wavy chain structure that is extended by hydrogen-bonding interactions to form a supramolecular network. The bioactivity of the complex as a potential PTPs inhibitor in vitro was investigated, displaying potent inhibition against PTP1B（IC（50）, 0.24 μM） and TCPTP（IC（50）, 0.53 μM） with a moderate selectivity.
The reaction of the reduced Schiff base HL（N-（4-hydroxybenzyl）-L-serine） with Zn（CH3COO）2·2H2O in aqueous solution afforded [Zn（L）2]·3H2O（I）. The complex has been characterized by elemental analysis, FT-IR, powder X-ray diffraction, electrospray ionization mass spectrometry and single-crystal X-ray diffraction. Complex I crystallizes in the orthorhombic system, space group P212121, with a=9.197（2）, b=10.445（2）, c=24.149（5） , V=2319.8（8） 3, Z=4, C（20）H（30）N2O11 Zn, Mr=539.83, Dc=1.546 g·cm3, μ=1.122 mm（-1）, F（000）=1128, GOOF=0.971, the final R=0.0206 and w R=0.0506 for 4346 observed reflections（I ＆gt; 2σ（I））. In complex I, each Zn（II） ion coordinates with three carboxyl oxygen atoms and two amine nitrogen atoms from three L-anions, forming a distorted five-coordinated trigonal bipyramidal geometry. Complex I exhibits a 1D wavy chain structure that is extended by hydrogen-bonding interactions to form a supramolecular network. The bioactivity of the complex as a potential PTPs inhibitor in vitro was investigated, displaying potent inhibition against PTP1B（IC（50）, 0.24 μM） and TCPTP（IC（50）, 0.53 μM） with a moderate selectivity.
基金
Supported by NNSFC(Nos.21271121,21471092,21571118)
